T1230-06-37

Sripriya Ranganathan, Ilia V. Davydov, Laura Schaefer, Jeff Debad, and Jacob N. Wohlstadter Meso Scale Discovery, Rockville, Maryland USA

CONTACT INFORMATION: sharkins@meso-scale.com

PURPOSE

Novel developments in immuno-oncology research have driven an increased demand for the sensitive measurement of biomarkers associated with cancer, immune responses, and targets of therapeutic drugs. The levels of these biomarkers are frequently altered in samples from cancer patients and can be evaluated by measuring their concentrations in blood and tissue lysate samples. We had previously developed and launched 27 immuno-oncology assays targeting both traditional and emergent cancer biomarkers. We now report expansion of this group with the introduction of 24 additional assays. The assays are available on the U-PLEX platform and can be multiplexed with 80 other U-PLEX assays. The combined group of 131 assays allows for flexible and simultaneous measurements of immuno-oncology, inflammation, and metabolic analytes.

METHODS

Electrochemiluminescence Technology

MSD's electrochemiluminescence detection technology uses SULFO-TAG[™] labels that emit light upon electrochemical stimulation initiated at the electrode surfaces of MULTI-ARRAY® and MULTI-SPOT[®] microplates.

- Minimal background, combined with strong response to analyte, yields high signal-to-noise ratios
- The stimulation mechanism (electricity) is decoupled from the response (light signal), minimizing matrix interference.
- Only labels bound near the electrode surface are excited, enabling non-washed assays.
- Labels are stable, non-radioactive, and directly conjugated to biological molecules.
- Emission at ~620 nm eliminates problems with color quenching.
- Multiple rounds of label excitation and emission enhance light levels and improve sensitivity.

U-PLEX® Immuno-Oncology Protocol


The U-PLEX assay platform uses 10 unique linkers that specifically bind to individual spots, enabling simple and flexible creation of multiplex immunoassays.


Couple and Coat the U-PLEX Plate:

- Add 200 μ L of the biotinylated capture antibody to 300 μ L of the assigned linker. Vortex. Incubate for 30 minutes.
- Add 200 µL of Stop Solution and vortex. Incubate for 30 minutes.
- Combine each U-PLEX-coupled antibody solution into a single tube and vortex. Add 50 µL of multiplex coating solution to each well.
- Incubate with shaking for 1 hour then wash the plate.

Complete the Assay:

- Add 50 µL of sample, calibrator, or control to each well.
- Incubate the plate for 2 hours, then wash the plate.
- Add 50 μL of detection antibody solution to each well.
- Incubate the plate for 1 hour, then wash the plate.
- Add 150 µL of MSD[®] Read Buffer to each well and read the plate.





Expansion of Human Immuno-Oncology Assays on a Multiplexed Electrochemiluminescence Platform David Cheo, Christopher Shelburne, Pu Liu, Teri Girtsman, Priscilla Krai, Seth Harkins,



RESULTS

Assay Characteristics

Calibrator curves, lower limit of detection (LLOD), and upper limit of detection (ULOD) for 24 new human immuno-oncology assays are shown below. LLODs were calculated from 3 runs each with >20 blank wells. Control samples for each assay showed expected precision and accuracy, with intra-run CVs less than 10%, inter-run CVs less than 25%, and recoveries largely within 70-130% of target concentrations (data not shown).

	107		Analyte	LLOD-ULOD (pg/mL)	
Signal	10 ⁶ -	— <mark>→</mark> E-Selectin — , Galectin-9	APRIL/TNFSF13	7.47 - 45,000	
	105-	→ HVEM/TNFRSF14 → ICOS	E-Selectin	45 - 200,000	
	104-	── ICOS-L/B7-H2 ─▲─ LIGHT/TNFSF14	Galectin-9	0.41 - 5,500	
		─ ▼ MIG	HVEM/TNFRSF14	0.53 - 5,000	
	10 ³ -		ICOS	1.78 - 9,000	
	10 ²		ICOSL/B7-H2	0.98 - 12,000	
	10 ⁻¹ 10 ⁰ 10 ¹ 10 ² 10 ³ 10 ⁴ 10 ⁵ 10 Concentration (pg/mL)	6	LIGHT/TNFSF14	0.58 - 5,000	
			MIG	0.73 - 4,000	
	106-	— — MMP-1 → MMP-2	MMP-1	1.35 - 15,000	
	105-	— ▼ MMP-7 → MMP-9 (pro)	MMP-2	10.4 - 40,000	
Signal		→ MMP-9 (total) → Nectin-4	MMP-7	1.83 - 9,000	
0	104-	→ PD-L1 (EP2) → Pentraxin 3	proMMP-9	0.88 - 15,000	
	10 ³ -		MMP-9 (total)	1.61 - 10,000	
			Nectin-4	0.55 - 1,500	
	10^{2} + + + + + + + + + + + + + + + + + + +	5	PD-L1 (epitope 1)	11.7 - 40,000	
	Concentration (pg/mL)		Pentraxin 3	1.92 - 20,000	
	106-	─ ■ Perforin ─ ▲ P-Selectin	Perforin	1.42 - 15,000	
		→ RAGE (soluble)	P-Selectin	10.5 - 40,000	
Signal	105-		RAGE (soluble)	0.26 - 2,000	
Sić	104-	→ TNF-RI	RANTES	0.41 - 1,500	
	10 ³ -		S100A12	0.1 - 750	
			TNF-RI	0.15 - 1,000	
	10 ² 10 ¹ 10 ¹ 10 ² 10 ³ 10 ⁴ 10	5	TNF-RII	1.6 - 7,000	
	Concentration (pg/mL)		VEGFR-1/Flt-1	2.69 - 15,000	

U-PLEX Biomarker Compatibility


Compatibility with existing human U-PLEX immuno-oncology assays was tested using dynamic range, sensitivity, sample detection, and non-specific binding as performance criteria. As a result, the U-PLEX Immuno-Oncology Group 1 (human) panel was expanded to 131 assays (see the table below) that can be multiplexed together.

APRIL/TNFSF13	Galectin-9	IL-1α	IL-17E/IL-25	MIF	P-Selectin
BAFF-R/TNFRSF13C	G-CSF	IL-1ß	IL-17F	MIG	PYY (total)
BCMA/TNFRSF17	Ghrelin (active)	IL-1RA	IL-18	MIP-1a	RAGE (soluble)
CD20	GIP (active)	IL-2	IL-21	MIP-1ß	RANKL/TNFSF11
CD27	GIP (inactive)	IL-2Rα	IL-22	MIP-5	RANTES
CD276/B7-H3	GITR/TNFRSF18	IL-3	IL-23	MMP-1	S100A12
CD28	GITRL/TNFSF18	IL-4	IL-27	MMP-2	SDF-1a
CD40L (soluble)	GLP-1 (active)	IL-5	IL-29/IFN-λ1	MMP-7	Tie-2
C-Peptide	GLP-1 (inactive)	IL-6	IL-31	proMMP-9	TIGIT
СТАСК	GM-CSF	IL-7	IL-33	MMP-9 (total)	TLR1
CTLA-4	gp130 (soluble)	IL-8	Insulin	Nectin-4	TNF-α
ENA-78	Granzyme A	IL-9	IP-10	OX40/TNFRSF4	TNF-RI
Eotaxin	Granzyme B	IL-10	I-TAC	PD1 (epitope 1)	TNF-RII
Eotaxin-2	GRO-α	IL-12/IL-23p40	LAG3	PD1 (epitope 2)	TNF-ß
Eotaxin-3	HAVCR2/TIM-3	IL-12p70	Leptin	PD-L1 (epitope 1)	TPO
EPO	HVEM/TNFRSF14	IL-13	LH	PD-L1 (epitope 1)	TRAIL
E-Selectin	I-309	IL-15	LIGHT/TNFSF14	PD-L2	TSLP
FGF (basic)	ICOS	IL-16	MCP-1	Pentraxin 3	VEGF-A
FGF-23	ICOSL/B7-H2	IL-17A	MCP-2	Perforin	VEGF-D
FLT3L	IFN-α2a	IL-17A/F	MCP-4	PIGF	VEGFR-1/Flt-1
Fractalkine	IFN-ß	IL-17C	M-CSF	РР	YKL-40
FSH	IFN-γ	IL-17D	MDC	Proinsulin	


Plarm Sci 360

Native Sample Testing

Immuno-oncology assays were evaluated for the ability to detect their respective analytes in human serum, EDTA plasma, and citrate plasma samples. Sample concentrations (pg/mL) were plotted with the top of curve (TOC) and LLOD for each analyte. Samples were diluted 4-fold except for ICOSL/B7-H2, MMP-2, proMMP-9, MMP-9 (total), P-Selectin, RANTES, S100A12, TNF-RI and TNF-RII assays where samples were diluted 100-fold. ICOS was not detected in human serum and plasma samples. All other analytes were detected irrespective of the type of matrix.




Human tissue lysate samples (6.25 µg) derived from different normal tissues (blue symbols) and tumor tissues (red symbols) were tested. Sample concentrations (pg/mL) were plotted with TOC and LLOD values for each analyte. All analytes were detected in most of the tissue lysate samples.



Dilution Linearity

Serum and EDTA plasma samples were spiked with calibrator and diluted 2, 4, 8, and 16-fold before testing. Sample concentrations were normalized to the 4-fold sample dilution. For ICOS-L/B7-H2, MMP-2, proMMP-9, MMP-9 (total), P-Selectin, RANTES, S100A12, TNF-RI and TNF-RII, unspiked samples were diluted 50, 100, 200 and 400-fold. Sample concentrations for these were normalized to the 100-fold sample dilution. Most analytes recovered within 70-130% in each type of sample. Recovery of MIG improved with the addition of 0.1% Triton X-100 (data not shown).



Assay Interference and Competition


Immuno-oncology assays were evaluated for interference and competition with therapeutic antibody drugs and homologous and/or related analytes. Assay interference was measured by comparing recovery of analyte in the presence of a wide concentration range of the potential interferent. Competition was measured by comparing human serum and plasma sample concentrations in singleplex and multiplex formats. Percent change from control was reported in the table below (% change >50% shaded red, <50% shaded yellow, <20% shaded green). Testing with therapeutic antibody drugs demonstrated that the PD1 (epitope 1) assay is more resistant to Nivolumab and Pembrolizumab than PD1 (epitope 2). Similarly, PD-L1 (epitope 2) is more resistant to Atezolizumab than PD-L1 (epitope 1). Assay

The U-PLEX immuno-oncology assay portfolio has expanded to 51 assays with the addition of twenty-four new human assays. U-PLEX immuno-oncology assays can be used in singleplex and multiplex formats and can be run in combination with 80 additional biomarker assays bringing the total number of compatible assays to 131. These assays enable researchers and drug developers to simultaneously measure immuno-oncology analytes along with cytokines, chemokines, and inflammatory markers.



Spike Recovery

Normal human serum and EDTA plasma samples were spiked with calibrators at 3 levels (high, mid, and low). Spike recovery values for the three spike levels were averaged and plotted. Recovery of most analytes was within 70-130% in each sample type.



Assay	Interferent	Impact	Assay	Interferent	Impact	Assay	Interferent	Impact
APRIL/	BAFF-R/TNFRSF13C		gp130 (soluble)	IL-6	—	PD-L1	PD-1	
TNFSF13	BCMA/TNFRSF17		HVEM/TNFRSF14	LIGHT/TNFSF14	—	(epitope 2)	Atezolizumab	-17%
	APRIL/TNFSF13		HVACR2/TIM-3	Galectin-9	—	PD-L2	PD1	
BAFF-R/	BAFF	_	ICOS	ICOS-L/B7-H2	—		PD-L1	
TNFRSF13C	BCMA/TNFRSF17		ICOS-L/B7-H2	ICOS	+20%	Perforin	Granzyme A	
	TACI/TNFRSF13B		LIGHT/TNFSF14	HVEM/TNFRSF14	—	PIGF	VEGFR-1/Flt-1	
BCMA/	APRIL/TNFSF13		OX40/TNFRSF4	OX40L/TNFSF4	—	RANKL/TNFSF11	Osteoprotegerin	
TNFSF17	BAFF			Nivolumab	-33%	TIGIT	CD155	
6039	CD80/B7-1		PD1 (epitope 1)	Pembrolizumab	-19%	TNF-α	TNF-RI	
CD28	CTLA-4			PD-L1	—	τnf-β	TNF-RI	
	Ipilimumab	-90%		PD-L2	_		TNF-RII	
CTLA-4	CD28		PD1	Nivolumab	-99%		TNF-α	
	CD80/B7-1	_	(epitope 2)	Pembrolizumab	-98%	TNF-RI	TNF-β	_
Galectin-9	HVACR2/TIM-3		PD-L1	Atezolizumab	-91%	TNF-RII	TNF-β	
Cueren a A	Perforin	_		PD1	—	VEGF-A	VEGFR-1/Flt-1	
Granzyme A	Prot. Inhibitors		(epitope 1)	PD-L2	—	VEGFR-1/Flt-1	PIGF	-27%
GITR/TNFSRF18	GITRL/TNFSF18							

CONCLUSIONS

SCOVERY, Meso Scale Diagnostics, MSD, mesoscale.com, www.mesoscale.com, methodicalmind.con www.methodicalmind.com, DISCOVERY WORKBENCH, InstrumentLink, MESO, MesoSphere, Methodical Mind, MSD GOLD MULTI-ARRAY. MULTI-SPOT. QuickPlex. ProductLink. SECTOR. SECTOR HTS. SECTOR PR. SULFO-TAG. TeamLink. TURBO-BOOST, TURBO-TAG, N-PLEX, R-PLEX, S-PLEX, T-PLEX, U-PLEX, V-PLEX, MSD (design), MSI (luminous design), Methodical Mind (head logo), 96 WELL SMALL-SPOT (design), 96 WELL 1-, 4-, 7-, 9-, & 10-SPOT (designs), 384 WELL 1- & 4-SPOT (designs), N-PLEX (design), R-PLEX (design), S-PLEX (design), T-PLEX (design), U-PLEX (design), V-PLEX (design), It's All About U, Spot the Difference, The Biomarker Company, and The Methodical Mind Experience are trademarks and/or service marks owned by or licensed to Meso Scale Diagnostics, LLC. All other trademarks and service marks are the property of their respective owners.